What is a stock summary page? Click here for an overview.
Business Description
Biosergen AB
ISIN : SE0016013460
Compare
Compare
Traded in other countries / regions
BIOSGN.Sweden8N1.Germany IPO Date
2021-07-01Description
Biosergen AB is a biotech company developing innovative antifungal drugs based on latest biopharmaceutical research and development from laboratory facilities in Trondheim, Norway, and several other places worldwide. The company is developing BSG005, a potentially disruptive antifungal drug, which has demonstrated significant safety and potency advantages over competing antifungals.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.93 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 45.8 | |||||
| 3-Year EPS without NRI Growth Rate | 40.7 | |||||
| 3-Year FCF Growth Rate | 49.5 | |||||
| 3-Year Book Growth Rate | -17.9 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23 | |||||
| 9-Day RSI | 30.51 | |||||
| 14-Day RSI | 34.91 | |||||
| 3-1 Month Momentum % | -21.05 | |||||
| 6-1 Month Momentum % | -15.49 | |||||
| 12-1 Month Momentum % | 25.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.25 | |||||
| Quick Ratio | 14.25 | |||||
| Cash Ratio | 13.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -63.7 | |||||
| Shareholder Yield % | -85.12 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -103.68 | |||||
| ROA % | -86.77 | |||||
| ROIC % | -241.27 | |||||
| 3-Year ROIIC % | 1287.53 | |||||
| ROC (Joel Greenblatt) % | -320.61 | |||||
| ROCE % | -102.67 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.49 | |||||
| Price-to-Tangible-Book | 1.41 | |||||
| EV-to-EBIT | -1.33 | |||||
| EV-to-Forward-EBIT | -6.76 | |||||
| EV-to-EBITDA | -1.33 | |||||
| EV-to-FCF | -1.68 | |||||
| Price-to-Net-Current-Asset-Value | 1.41 | |||||
| Price-to-Net-Cash | 1.41 | |||||
| Earnings Yield (Greenblatt) % | -75.16 | |||||
| FCF Yield % | -20 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Biosergen AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.013 | ||
| Beta | 2.29 | ||
| 3-Year Sharpe Ratio | -0.06 | ||
| 3-Year Sortino Ratio | -0.12 | ||
| Volatility % | 160.02 | ||
| 14-Day RSI | 34.91 | ||
| 14-Day ATR (€) | 0.002032 | ||
| 20-Day SMA (€) | 0.03148 | ||
| 12-1 Month Momentum % | 25.87 | ||
| 52-Week Range (€) | 0.0194 - 0.0874 | ||
| Shares Outstanding (Mil) | 234.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biosergen AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biosergen AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Biosergen AB Frequently Asked Questions
What is Biosergen AB(FRA:8N1)'s stock price today?
The current price of FRA:8N1 is €0.03. The 52 week high of FRA:8N1 is €0.09 and 52 week low is €0.02.
When is next earnings date of Biosergen AB(FRA:8N1)?
The next earnings date of Biosergen AB(FRA:8N1) is 2025-05-21.
Does Biosergen AB(FRA:8N1) pay dividends? If so, how much?
Biosergen AB(FRA:8N1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers